

# ForPatients

by Roche

Wet Age-Related Macular Degeneration

## A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

**Trial Status**

Not Yet Recruiting

**Trial Runs In**

0 Countries

**Trial Identifier**

NCT06847542 2024-516924-32-00  
MR45625

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.

**Hoffmann-La Roche**

Sponsor

**Phase 3**

Phase

---

**NCT06847542 2024-516924-32-00 MR45625**

Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**

All

**Age**

>=50 Years

**Healthy Volunteers**

No

---